Review article: Volume expansion in patients with cirrhosis

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 16, Issue 5, 2002, Pages 12-23

  Henriksen, J H ^a,b   Kiszka Kanowitz, M ^a   Bendtsen, F ^a   Moller S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; PLASMA SUBSTITUTE; SODIUM CHLORIDE; WATER; SERUM ALBUMIN;

ARTERY COMPLIANCE; BLOOD VOLUME; CARDIOVASCULAR DISEASE; HORMONAL REGULATION; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE; FLUID THERAPY; HEMODYNAMICS; METHODOLOGY; PATHOPHYSIOLOGY;

BLOOD VOLUME; FLUID THERAPY; HEMODYNAMIC PROCESSES; HUMANS; LIVER CIRRHOSIS; PLASMA SUBSTITUTES; SERUM ALBUMIN;

EID: 1642573888     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.16.s5.3.x     Document Type: Review

References (99)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laënnecs cirrhosis. J Clin Invest 1953; 32: 1025-33.
2. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-67.
3. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch, J, Groszmann, RJ, eds. Portal Hypertension. Pathophysiology and Treatment. Oxford. UK: Blackwell 1994: 17-26.
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis, a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 5: 1151-7.
5. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver. Its relations to portal hypertension, ascites, and renal failure. J Clin Invest 1967; 47: 1297-308.
6. Kiszka-Kanouwitz M, Henriksen JH, Moller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35: 605-12.
7. Henriksen JH, Bendtsen F, Sorensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-13.
8. Moller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001; 15: 94-106.
9. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
10. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol 1998; 29: 328-11.
11. Moller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996: 56: 481-90.
12. Arroyo V, Bosch J, Mauri M, et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979; 9: 69-73.
13. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307: 1552-7.
14. Colombato LA, Albillos A, Groszmann RJ. The role of central blood Volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996; 110: 193-8.
15. Hcnriksen JH, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999; 31: 712-8.
16. Henriksen JH, Moller S, Schifter S, Abrahamsen J, Bccker U. High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut 2001; 49: 112-8.
17. Moller S, Henriksen JH. The systemic circulation in cirrhosis. In: Arroyo V, Ginès P, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Maiden, MA: Blackwell Science, 1999: 307-29.
18. Rowell LB. Human Cardiovascular Control. New York/Oxford: Oxford University Press. 1993: 1-500.
19. Stergiopulos N, Meister J-J, Westerhof N. Evaluation of methods for estimation of total arterial compliance. Am J Physiol Hear Circ Physiol 1995; 268: H1540-8.
20. Nicholls KM, Shapiro MD, Van Putten VJ, et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res 1985; 56: 457-61.
21. Epstein M. Renal effects of head-out water immersion in man: implications for an understanding of volume homeostasis. Physiol Rev 1978; 58: 529-81.
22. Claria J, Jimenez W, Arroyo V, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989; 97: 1294-9.
23. Michel CC. Transport of macromolecules through microvascular walls. Cardiovasc Res 1996; 32: 644-53.
24. Jonassen TE, Nielsen S, Christensen S, Petersen JS. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol 1998; 275: F216-25.
25. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 1896; 19: 312-26.
26. Taylor A, Granger DN. Exchange of macromolecules across the microcirculation. In: Renkin EM, Michel CC, eds. Handbook of Physiology, Section 2: the Cardiovascular System, Vol. IV. Bethesda. MD: American Physiology Society, 1984: 467-520.
27. Henriksen JH. Protein-kinetics and haemodynamic studies in patients with liver cirrhosis. Clin Physiol 1981; 1: 565-78.
28. Henriksen JH, Siemssen O, Krintel JJ, Malchow-Moller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001: 34: 53-60.
29. Parving HH, Rossing N, Jensen HA. Increased metabolic turnover rate and transcapillary escape rate of albumin in essential hypertension. Circ Res 1974; 35: 544-52.
30. Joffe P, Henriksen JH. Bidirectional peritoneal transport of albumin in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1995: 10: 1725-32.
31. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 1974: 15: 99-101.
32. Hadengue A, Moreau R, Gaudin C, Bacq Y, Champigneulle B, Lebrec D. Total effective vascular compliance in patients with cirrhosis. A study of the response to acute blood volume expansion. Hepatatology 1992: 15: 809-15.
33. Andreu V, Perello A, Mointinho E, et al. Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. J Hepatol 2002; 36: 356-61.
34. Johansen LB, Foldager N, Stadeager C, et al. Plasma volume, fluid shifts, and renal responses in humans during 12 h of head-out water immersion. J Appl Physiol 1992; 73: 539-44.
35. Gerbes AL, Pilz A, Wernze H, Jungst D. Renal sodium handling and neurohumoral systems in patients with cirrhosis in sitting posture: effects of spironolactone and water immersion. Clin Invest 1993; 71: 894-7.
36. Warner LC, Morali GA, Miller JA, Logan AG, Skorecki KL, Blendis LM. Aldosterone, atrial natriuretic factor and sodium intake as determinants of the natriuretic response to head-out water immersion in healthy subjects. Clin Sci (Lond) 1991; 80: 475-80.
37. Gerbes AL, Arendt RM, Gerzer R, et al. Role of atrial natriuretic factor, cyclic GMP and the renin-aldosterone system in acute volume regulation of healthy human subjects. Eur J Clin Invest 1988; 18: 425-9.
38. Scheuermann-Freestone M, Freestone NS, Langenickel T, Hohnel K, Dietz R, Willenbrock R. A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail 2001; 3: 535-43.
39. de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten A. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001; 79: 705-14.
40. Levy M, Wexter MJ. Renal sodium retention and ascites formation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity. J Lab Clin Med 1978; 91: 520-36.
41. Bradley SE, Marks PA, Reynall PC, Meltzer J. The circulating splanchnic blood volume in dog and man. Trans Ass Am Physns 1953; 66: 294-302.
42. Larsen OA, Tygstrup N, Winkler K. The splanchnic hematocrit in man. Acta Physiol Scand 1963; 57: 397-406.
43. Larsen OA, Winkler K, Tygstrup N. 'Extra' plasma in the liver calculated from the hepatic hematocrit in patients with portacaval anastomosis. Clin Sci 1963; 25: 357-60.
44. La Villa G, Barlctta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27.
45. La Villa G, Lazzeri C, Pascale A, et al. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis. Am J Gastroenterol 1997: 92: 852-7.
46. La Villa G, Riccardi D, Lazzeri C, et al. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology 1995; 22: 1745-50.
47. Gentilini P, Romanelli RG, Laffi G, et al. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999; 30: 632-8.
48. Camps J, Sola J, Arroyo V, et al. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987; 93: 498-505.
49. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
50. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A Prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
51. Abraham WT, Schrier RW. Extracellular fluid volume homeostasis. In: Arroyo V, Ginès P, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Malden, MA: Blackwell Science, 1999: 129-42.
52. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996: 24: 451-9.
53. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999; 97: 259-67.
54. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-7.
55. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15.
56. Hasch E, Jarnum S, Tygstrup N. Albumin synthesis rate as a measure of liver function in patient with cirrhosis. Acta Med Scand 1967; 182: 83-92.
57. Dichi JB, Dichi I, Maio R, et al. Whole-body protein turnover in malnourished patients with child class B and C cirrhosis on diets low to high in protein energy. Nutrition 2001; 17: 239-42.
58. Dumont AE, Mulholland JH. Flow rate and composition of thoracic-duct lymph in patients with cirrhosis. N Engl J Med 1960; 263: 471-1.
59. Bengmark S. The Peritoneum and Peritoneal Access. London: Wright 1989, 1-374.
60. Henriksen JH, Stage JG, Schlichting P, Winkler K. Intraperitoneal pressure: Ascitic fluid and splanchnic vascular pressures, and their role in prevention and formation of ascites. Scand J Clin Laboratory Invest 1980; 40: 493-502.
61. Salo J, Ginès A, Ginès P, et al. Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997; 27: 645-53.
62. Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 1980; 78: 1059-68.
63. Witte MH, Witte CL, Dumont AE. Estimated net transcapillary water and protein flux in the liver and intestine of patients with portal hypertension from hepatic cirrhosis. Gastroenterology 1981; 80: 265-72.
64. Stanley MM, Shigeru O, Lee KK, Nemchausky BA, Greenlee HB, Alien JI. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 1989; 321: 1632-8.
65. Ginès A, Planas R, Angeli P, et al. Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. Hepatology 1995; 22: 124-31.
66. Henriksen JH. Abnormalities in transsinusoidal fluid exchange in cirrhosis. Local factors in ascites formation. In: Arroyo V, Bosch J, Bruguera M, Rodés J, eds. Therapy in Liver Disease. The Pathological Basis of Therapy. Barcelona. Spain: Masson SA, 1997: 51-62.
67. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, Mc-Hutchison JG. The serum-ascites albumin gradient is superior to the exudates-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992: 117: 215-20.
68. Arroyo V, Sort P, Gines P, Planas R. Treatment of ascites by paracentesis. In: Arroyo V. Ginès P, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Maiden, MA: Blackwell Science, 1999: 463-79.
69. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 829-35.
70. Zaak D, Paquet KJ, Kuhn R. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol 2001; 39: 5-10.
71. Garcia-Compean D, Zacarias VJ, Bahena CH, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomised controlled trial. Liver 1993; 13: 233-8.
72. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22: 753-8.
73. Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
74. Ginès A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascitcs treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
75. Gcntilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites; results of a randomized, controlled trial. J Hepatol 1999; 30: 639-15.
76. Ginès P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomised study. Gastroenterology 1987; 93: 234-41.
77. Salerno F, Badalmenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987; 5:102-8.
78. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707-13.
79. Fassio E, Terg R, Landeira G, et al. Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomised study. J Hepatol 1992; 14: 310-6.
80. Planas R, Gines P, Arroyo V, et al. Dextran-70 vs. albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomised study. Gastroenterology 1990; 99: 1736-4.
81. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch vs. albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998; 10: 5-10.
82. Tito L, Ginès P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990; 98: 146-51.
83. Sola R, Vila MC, Andreu M, et al. Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J Hepatol 1994: 20: 282-8.
84. Wong F, Tobe S, Legault L, Logan AG, Skorecki K, Blendis LM. Refractory ascites in cirrhosis, roles of Volume expansion and plasma atrial natriuretic factor level elevation. Hepatology 1993; 18: 519-28.
85. Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 709-19.
86. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32(Suppl. 1): 157-70.
87. Ginès P, Arroyo V. Is there still a need for albumin infusions to treat patients with liver disease? Gut 2000; 46: 588-90.
88. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance. Am J Physiol Gastrointestinal Liver Physiol 2001; 280: G584-94.
89. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998; 317: 235-40.
90. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. Ann Intern Med 2001; 135: 149-64.
91. Adam R, Astarcioglu I, Castaing D, Bismuth H. Ringer's lactate vs. serum albumin as a flush solution for UW preserved liver grafts: results of a prospective randomized study. Transplant Proc 1991; 23: 2374-5.
92. Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet 1962; ii: 1125-9.
93. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
94. Castaneda B, Moreles J, Liontti R, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anaesthetized cirrhotic rats. Hepatology 2001; 33: 821-5.
95. Henriksen JH, Bendtsen F, Moller S. Normal red cell cardiac output in the hyperkinetic syndrome of alcoholic cirrhosis. J Hepatol 2001; 34: 782-3.
96. Morcau R, Lee SS, Hadenque A, Ozier Y, Sicot C, Lebrec D. Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: effects of vasoactive drugs. Hepatology 1989; 9: 427-32.
97. Moller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1996; 25: 316-28.
98. Elizalde JI, Moitinho E, Carcia-Pagán JC, et al. Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. J Hepatol 1998; 29: 789-95.
99. Cirera I, Elizalde JI, Piqué JM, et al. Anaemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Dig Dis Sci 1997; 42: 1697-702.